The earnings call for Johnson & Johnson highlights strong performance in the pharmaceutical sector, driving overall earnings growth. However, the medical device segment faced continued market and pricing pressures, particularly noted in orthopedics where pricing challenges persist. While the company maintains a robust pipeline with XPSAPI/ESAPI delays and a reduced 2008 forecast might constrain growth, positive developments in other areas such as the integration of Synthes and global expansion could offset some of the negative pressures. The guidance for 2013 seems optimistic, suggesting stability despite the mixed results. 

[1]